Novo Nordisk's next-gen obesity drug Cagrisema: investors seek …
2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that …
News Details - novonordisk.com
Dec 20, 2024 · Once-weekly subcutaneous CagriSema is being investigated by Novo Nordisk as a treatment for adults with overweight or obesity (REDEFINE programme) and as a treatment …
Investors grow anxious at Novo Nordisk's silence over CagriSema …
1 day ago · Investors are growing anxious about Novo Nordisk’s silence since disappointing CagriSema weight loss drug results BY Ryan Hogg Novo Nordisk is set to release annual …
Novo Nordisk Faces Investor Concerns Over Hybrid CagriSema …
1 day ago · In November, Novo Nordisk said its hybrid drug, CagriSema, aims to reduce weight by 25% without added side effects. A key issue emerging from the trial is that only 57.3% of …
Novo Nordisk’s next-generation weight-loss drug CagriSema
Dec 20, 2024 · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t …
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
Dec 20, 2024 · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its …
Novo Nordisk A/S: CagriSema demonstrates superior weight loss …
Dec 20, 2024 · REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) …
Novo Nordisk affirms 25% weight-loss expectation for …
Nov 6, 2024 · Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its …
News Details - Novo Nordisk
Bagsværd, Denmark, 22 August 2022 – Novo Nordisk today announced headline results from a phase 2 clinical trial with CagriSema, a once-weekly subcutaneous combination of …
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
2 days ago · Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial results that …